Stoicescu Claudiu, Vintila Vlad, Udroiu Cristian, Florescu Nicolae, Dawood Aws, Cinteza Mircea, Vinereanu Dragos
"Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
University Emergency Hospital, Bucharest, Romania.
Maedica (Bucur). 2013 Jun;8(2):153-63.
Stent thrombosis (ST) is a rare, but extremely severe complication of PCI. Outside clinical trials, data are limited regarding the risks and the impact of this phenomenon.
To assess prevalence, predictors, and clinical outcome of ST after implantation of drug eluting stents (DES) compared with bare metal stents (BMS), in a large case-control study in a real world scenario, as well as the relation between ST and duration of combined antiplatelet treatment.
In a case-control registry we included 475 patients who received at least 1 DES (sirolimus, zotarolimus, everolimus, paclitaxel), compared with a group of 475 patients who received at least 1 BMS. We used 1.22 DES/patient vs. 1.26 BMS/patient (p=ns), treating 1.02 DES/lesion vs. 1.05 BMS/lesion (p=ns). Main outcome was ST defined by the Academic Research Consortium (ARC) as definite (acute, sub-acute, late), probable, and possible.
At 15 months we found 0.8% (4) patients in the DES group vs. 1.1% (5) patients in the BMS group with definite ST (ns); 0.4% (2) patients from each group had acute ST, while 0.4% (2) vs. 0.7% (3) patients had sub-acute ST (both comparisons were ns). None of the patients from the DES group died, whereas two patients with definite ST from the BMS group died, with a case fatality rate of 40% (2/5). 0.2% (1) patient from each group had probable ST (ns) and 0.6% (3) vs. 0.4% (2) patients had possible ST (ns). Independent predictors of stent thrombosis in merged groups were antiplatelet therapy discontinuation (HR 3.8; 95%CI 1.9-7.6; p<0.01), diabetes (HR 2.15; 95%CI 1.4-5.1; p<0.01), a lower left ventricular ejection fraction (EF) (HR 1.1; 95%CI 1.0-1.9; p<0.01 for each 10% decrease), and LAD lesions (HR 1.0; 95%CI, 0.93-1.9; P<0.01).
ST is a rare complication (0.95%), similar after DES or BMS implantation. Premature discontinuation of antiplatelet therapy, followed by diabetes and a lower LVEF, are the independent predictors of ST.
支架内血栓形成(ST)是经皮冠状动脉介入治疗(PCI)一种罕见但极其严重的并发症。在临床试验之外,关于这一现象的风险和影响的数据有限。
在一项真实世界场景下的大型病例对照研究中,评估药物洗脱支架(DES)与裸金属支架(BMS)植入后ST的发生率、预测因素及临床结局,以及ST与联合抗血小板治疗持续时间之间的关系。
在一个病例对照登记研究中,我们纳入了475例接受至少1枚DES(西罗莫司、佐他莫司、依维莫司、紫杉醇)的患者,并与475例接受至少1枚BMS的患者组进行比较。我们使用的DES/患者为1.22枚,BMS/患者为1.26枚(p=无显著性差异),DES/病变为1.02枚,BMS/病变为1.05枚(p=无显著性差异)。主要结局是由学术研究联盟(ARC)定义的明确(急性、亚急性、晚期)、可能和疑似ST。
在15个月时,我们发现DES组中有0.8%(4例)患者发生明确ST,BMS组中有1.1%(5例)患者发生明确ST(无显著性差异);每组有0.4%(2例)患者发生急性ST,而亚急性ST的患者分别为0.4%(2例)和0.7%(3例)(两项比较均无显著性差异)。DES组中无患者死亡,而BMS组中有2例明确ST患者死亡,病死率为40%(2/5)。每组有0.2%(1例)患者发生疑似ST(无显著性差异),可能ST的患者分别为0.6%(3例)和0.4%(2例)(无显著性差异)。合并组中支架内血栓形成的独立预测因素为抗血小板治疗中断(HR 3.8;95%CI 1.9 - 7.6;p<0.01)、糖尿病(HR 2.15;95%CI 1.4 - 5.1;p<0.01)、较低的左心室射血分数(EF)(每降低10%,HR 1.1;95%CI 1.0 - 1.9;p<0.01)和左前降支病变(HR 1.0;95%CI 0.93 - 1.9;P<0.01)。
ST是一种罕见并发症(0.95%),DES或BMS植入后相似。抗血小板治疗过早中断,其次是糖尿病和较低的左心室射血分数,是ST的独立预测因素。